$ACOGF News
Last published 2y ago
- 2y agoACOGFCSE:ACOGAlpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq UplistingBusiness WireAlpha Cognition Inc. (CSE:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), is pleased to announce that it has filed a registration statement on Form S-1 (the "Registration Statement") with the U.S. Securities
- 2y agoACOGFCSE:ACOGAlpha Cognition Announces Appointment of VP Finance and AccountingBusiness WireAlpha Cognition Inc. (CSE:ACOG) (OTCQB:ACOGF) ("Alpha Cognition" or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announces that Henry
- 2y agoACOGFCSE:ACOGAlpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer's DiseaseBusiness WireAlpha Cognition Inc. (CSE:ACOG) (OTCQB:ACOGF) (Alpha Cognition "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce
- 2y agoACOGFCSE:ACOGAlpha Cognition Announces Change of OfficerBusiness WireAlpha Cognition Inc. (CSE:ACOG) (OTCQB:ACOGF) ("Alpha Cognition" or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announces that Don
- 2y agoACOGFSpartan Capital Securities Serves as Selling Group Member in Alpha Cognition Inc.'s $4.454 Million Convertible Note and Warrants Bridge FinancingGlobeNewswireNew York, NY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities LLC, a leading investment banking firm, is pleased to announce its role as a selling group member in Alpha Cognition Inc.'s successful
- 2y agoACOGFCSE:ACOGAlpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge FinancingBusiness WireAlpha Cognition Inc. (CSE:ACOG) (OTCQB:ACOGF) ("Alpha Cognition" or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the
- 2y agoACOGFCSE:ACOGAlpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer's DiseaseBusiness WireAlpha Cognition Inc. (CSE:ACOG) (OTCQB:ACOGF) (Alpha Cognition "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announced
- 2y agoACOGFCSE:ACOGAlpha Cognition, Inc. On Track to Secure Financing for Continued GrowthBusiness WireAlpha Cognition (CSE:ACOG) (OTCQB:ACOGF) (Alpha Cognition "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, announced today its decision to
- 2y agoACOGFCSE:ACOGAlpha Cognition's Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's DiseaseBusiness WireThe Second Oral Therapy Approved This Decade, ZUNVEYL's Dual MOA Was Designed to Eliminate Drug Absorption in the Gastrointestinal (GI) Tract, Potentially Addressing Certain Tolerability Issues with Leading Alzheimer's
- 2y agoACOGFAlpha Cognition to Present at the Life Science Investor Forum March 7thGlobeNewswireVANCOUVER, British Columbia, March 01, 2024 (GLOBE NEWSWIRE) -- Alpha Cognition, Inc. (CSE:ACOG)(OTCQB:ACOGF), a biopharmaceutical company committed to developing novel therapies with the potential to transform the
- 2y agoACOGFCSE:ACOGAlpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer's DiseaseBusiness WireAlpha Cognition Inc. (CSE:ACOG) (OTCQB:ACOGF) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce
- 2y agoACOGFCSE:ACOGAlpha Cognition Provides Business UpdateBusiness WireAlpha Cognition Inc. (CSE:ACOG) (OTCQB:ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders provides a business update on it's ALPHA-1062 NDA filing for U.S.
- 2y agoACOGFCSE:ACOGAlpha Cognition Announces Final Closing of Private Placement Offering and Completion of the OverallotmentBusiness WireAlpha Cognition Inc. (CSE:ACOG, OTCQB:ACOGF) ("Alpha Cognition" or the "Company") announces that it has completed a final closing pursuant to its previously announced private placement of units of the Company. Pursuant
- 2y agoACOGFCSE:ACOGAlpha Cognition Announces Fourth Closing of Private Placement and Continuation of the OfferingBusiness WireAlpha Cognition Inc. (CSE:ACOG, OTCQB:ACOGF) ("Alpha Cognition" or the "Company") announces that it has completed a fourth closing pursuant to its previously announced private placement of units of the Company. Pursuant
- 2y agoACOGFCSE:ACOGAlpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer's DiseaseBusiness WireAlpha Cognition Inc. (CSE:ACOG) (OTCQB:ACOGF) (Alpha Cognition "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce
- 2y agoACOGFCSE:ACOGAlpha Cognition Announces Amended Terms of Private Placement and Continuation of the OfferingBusiness WireAlpha Cognition Inc. (CSE:ACOG, OTCQB:ACOGF) ("Alpha Cognition" or the "Company") announces that it has amended the terms of its previously announced private placement offering of up to US$6.5 million of units at a
- 3y agoACOGFCSE:ACOGAlpha Cognition Announces Third Closing of Private Placement and Continuation of the OfferingBusiness WireAlpha Cognition Inc. (CSE:ACOG, OTCQB:ACOGF) ("Alpha Cognition" or the "Company") announces that it has completed a third closing pursuant to its previously announced private placement of units of the Company. Pursuant
- 3y agoACOGFCSE:ACOGAlpha Cognition Announces Second Closing of Private Placement and Continuation of the OfferingBusiness WireAlpha Cognition Inc. (CSE:ACOG, OTCQB:ACOGF) ("Alpha Cognition" or the "Company") announces that it has completed a second closing pursuant to its previously announced private placement of units of the Company. Pursuant
- 3y agoACOGFCSE:ACOGAlpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the OfferingBusiness WireAlpha Cognition Inc. (CSE:ACOG, OTCQB:ACOGF) ("Alpha Cognition", or the "Company") announces the closing of its previously announced private placement of units of the Company for gross proceeds of US$1,345,093 before
- 3y agoACOGFCSE:ACOGAlpha Cognition Launches $6.5 Million Private PlacementBusiness WireAlpha Cognition Inc. (CSE:ACOG) (OTCQB:ACOGF) ("Alpha Cognition," or the "Company") announces a private placement offering of up to $6,500,000 of units at a price of $0.22 per unit. Each unit will consist of one common
- 3y agoACOGFTSX:ACOGTSXV:ACOGAlpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate UpdateBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
- 3y agoACOGFTSXV:ACOGAlpha Cognition Provides Private Placement UpdateBusiness WireNot for distribution in the United States or to U.S. newswire services Alpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company developing novel therapies for
- 3y agoACOGFTSXV:ACOGAlpha Cognition Announces Third Quarter 2022 Results and Provides Corporate UpdateBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
- 3y agoACOGFAlpha Cognition Announces Withdrawal of Marketed Public OfferingGlobeNewswireNOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. ("Alpha" or the "Company") (TSXV:ACOG) (OTCQB:ACOGF), a
- 3y agoACOGFAlpha Cognition Announces Marketed OfferingGlobeNewswireNOT FOR DISSEMINATION IN THE UNITED STATESOR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. ("Alpha" or the "Company") (TSXV:ACOG) (OTCQB:ACOGF), a
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announces Second Quarter 2022 Results and Provides Corporate UpdateBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer's DiseaseBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition," or the "Company"), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from a b
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer's DiseaseBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from its
- 4y agoACOGFAlpha Cognition to Webcast Live at VirtualInvestorConferences.com June 23rdGlobeNewswireVANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neu
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602Business WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease TreatmentBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the discovery of two GEM combinati
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announces Grant of Stock OptionsBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition," or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announces First Quarter 2022 Results and Company UpdateBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announces Fourth Quarter and Full Year 2021 Results and Company UpdateBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,
- 4y agoACOGFPTGXTSXV:ACOGAlpha Cognition Announces Change of CFO, Grant of Stock Options and Addition to the Board of DirectorsBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announces Positive Data from Pre-Clinical Studies of ALPHA-0602 (Progranulin) for Amyotrophic Lateral Sclerosis (ALS)Business WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disor
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announces Positive Neuroprotection Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain InjuryBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announces Participation in January Investor ConferencesBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announces Director Change and Stock Option GrantBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,
- 4y agoACOGFBABYFEMMAJNHMF+8Life Sciences Companies Investor Presentations Now Available for On-Demand ViewingPR NewswireNEW YORK, Dec. 20, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the December 16th Life Sciences Virtual Investor Conference are now available for on-de
- 4y agoACOGFBABYFEMMAHMTXF+7Life Sciences Virtual Investor Conference: Company Executives Present Live December 16thPR NewswireNEW YORK, Dec. 9, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the
- 4y agoACOGFTSXV:ACOGAlpha Cognition Announce Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain InjuryBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,
- 4y agoACOGFTSXV:ACOGAlpha Cognition Appoints Cedric O'Gorman, M.D., MBA as Chief Medical OfficerBusiness WireAlpha Cognition Inc. (TSXV:ACOG)(OTCQB:ACOGF)("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, to
- 4y agoACOGFTSXV:ACOGAlpha Cognition Reports Third Quarter of Fiscal 2021 ResultsBusiness WireAlpha Cognition Inc. (TSXV:ACOG) (OTCQB:ACOGF) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders,
- 5y agoAAZZFABIOACOGFACST+81Investor Summit Group Provides Update on Upcoming Q4 Virtual SummitGlobeNewswireNEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The Investor Summit Group, widely recognized for its reputation as the host of North America's largest independent investor conferences, will be hosting the upcoming Q4 Virtual Summit on November 16-17. The e
- 5y agoACOGFSRAXTSXV:ACOGAlpha Cognition to Present at LD Micro Main EventBusiness WirePresentation on Tuesday, October 12th at 3:00 PM EST Alpha Cognition Inc. (TSXV:ACOG)(OTCQB:ACOGF)("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of
- 5y agoACOGFTSXV:ACOGAlpha Cognition Provides CEO UpdateBusiness WireAlpha Cognition Inc. (TSXV:ACOG)(OTCQB:ACOGF)("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, ha
- 5y agoACOGFTSXV:ACOGAlpha Cognition Announces Formation and Members of Scientific Advisory Board and Investor Relations AgreementsBusiness WireAlpha Cognition Inc. (TSXV:ACOG)(OTCQB:ACOGF)("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, to
- 5y agoACOGFAlpha Cognition to Webcast Live at Life Sciences Investor Forum September 16thGlobeNewswireVANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Alpha Cognition, Inc. (TSXV:ACOG)(OTCQB:ACOGF)("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the
- 5y agoACOGFTSXV:ACOGAlpha Cognition Announces the Acceptance of its US FDA Investigational New Drug Application (IND) for Lead Candidate, ALPHA-1062 for Mild to Moderate Alzheimer's DiseaseBusiness WireAlpha Cognition Inc. (TSXV:ACOG)(OTCQB:ACOGF)("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is